jollibee 6 pcs www jilibet.com jollibee breakfast menu ubet casino login jolibet 3 login
Current location: jilibet slots > jollibee 6 pcs > how to win jili super ace

how to win jili super ace

Release time: 2025-01-24 | Source: Unknown
how to win jili super ace how to win jili super ace Syria's chemical weapons are under scrutiny after rebel forces ousted President Bashar al-Assad in Damascus, sparking fears of toxic materials falling into extremist hands. The Organisation for the Prohibition of Chemical Weapons ( OPCW) has reminded Syria of its international obligations to secure these weapons. The OPCW announced Monday it is "monitoring closely the recent developments in Syria, with special attention to the status of its chemical weapons -related sites and other locations of interest." The organization has also reached out to Syria's embassy in The Hague for assurances regarding compliance with the Chemical Weapons Convention . "To date, this work has continued, and the Syrian declaration of its chemical weapons programme still cannot be considered as accurate and complete," the OPCW statement said. Syria's 'Potentially Undeclared' Chemical Weapons Prime Minister Mohammed Ghazi Jalali, who remains in office , confirmed that most ministers are still operating in Damascus. He did not address concerns about the chemical stockpile, whose location and condition remain unclear. Syria's chemical arsenal, including sarin and chlorine-based weapons, has drawn international condemnation since it was linked to attacks during the earlier stages of the country's civil war . The worst incident killed over 1,400 people in Ghouta , near the capital. Syria declared 1,300 tons of banned chemical weapons after joining the OPCW in 2013. This was all destroyed, but weapons inspectors have since found evidence that contravenes the 1997 Chemical Weapons Convention supervised by the OPCW. Assad's government saw 28 chemical weapon inspections across 24 years. In this time the OPCW's reason to believe in the existence of undisclosed weapons has only grown––the most recent assessment saw "potentially undeclared full-scale development and production of chemical weapons at two declared chemical weapons-related facilities," said OPCW chief Fernando Arias in November. Extremist Acquisition of Weapons Prevented, Says Israel Israel has conducted airstrikes on suspected chemical weapons sites and long-range rocket facilities to prevent their acquisition by "extremists." "Since the initial hours after the announcement of the fall of the former regime, Israel began launching intensive air strikes, deliberately destroying weapons and ammunitions depots," UK-based monitoring group The Syrian Observatory for Human Rights (SOHR) said. Israel's foreign minister Gideon Saar on Monday said, "The only interest we have is the security of Israel and its citizens." "That's why we attacked strategic weapons systems, like, for example, remaining chemical weapons, or long-range missiles and rockets, in order that they will not fall in the hands of extremists." Russia Grants Assad Political Asylum Meanwhile, Assad has sought political asylum in Russia . Kremlin spokesperson Dmitry Peskov confirmed the arrangement but declined to comment on Assad's location or any planned meeting with Russian President Vladimir Putin . Assad's removal from power has created a political vacuum, with rebel leader Ahmad al-Sharaa—formerly known as Abu Mohammed al-Golani—emerging as a key figure. Assad has not made a public appearance since meeting with Iran's foreign minister in Damascus last week, where he pledged to "crush" the advancing rebels. Since then, forces led by former al-Qaeda commander Abu Mohammed al-Jawlani, now heading the militant group Hayat Tahrir al-Sham, have seized control of the capital and much of Assad's remaining territory. This article includes reporting from The Associated PressSnell, Dodgers agree to $182M, 5-year contractNone

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree” or "the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis [email protected] Consolidated Balance Sheets (in thousands, except share and per share data) Consolidated Statements of Operations (in thousands, except per share data)Techmediabreaks Quantum Computing Inc. (NASDAQ: QUBT) Announces Concurrent OfferingsDefensive back Genesis Smith to enter portal, upping Arizona’s transfer count to 30

Can We End Racism In Australia? Yes, According To The First-Ever National PlanFuture of Vertical Steam Sterilizers Market: Analysis and Leadership by Yamato Scientific, Matachana, Steelco, PRIMUS Sterilizer, Tuttnauer, Biobase, Steris, Shinva

FanDuel Promo Code: Steelers-Browns TNF $150 Bonus Offer

how to win jili super ace how to win jili super ace Syria's chemical weapons are under scrutiny after rebel forces ousted President Bashar al-Assad in Damascus, sparking fears of toxic materials falling into extremist hands. The Organisation for the Prohibition of Chemical Weapons ( OPCW) has reminded Syria of its international obligations to secure these weapons. The OPCW announced Monday it is "monitoring closely the recent developments in Syria, with special attention to the status of its chemical weapons -related sites and other locations of interest." The organization has also reached out to Syria's embassy in The Hague for assurances regarding compliance with the Chemical Weapons Convention . "To date, this work has continued, and the Syrian declaration of its chemical weapons programme still cannot be considered as accurate and complete," the OPCW statement said. Syria's 'Potentially Undeclared' Chemical Weapons Prime Minister Mohammed Ghazi Jalali, who remains in office , confirmed that most ministers are still operating in Damascus. He did not address concerns about the chemical stockpile, whose location and condition remain unclear. Syria's chemical arsenal, including sarin and chlorine-based weapons, has drawn international condemnation since it was linked to attacks during the earlier stages of the country's civil war . The worst incident killed over 1,400 people in Ghouta , near the capital. Syria declared 1,300 tons of banned chemical weapons after joining the OPCW in 2013. This was all destroyed, but weapons inspectors have since found evidence that contravenes the 1997 Chemical Weapons Convention supervised by the OPCW. Assad's government saw 28 chemical weapon inspections across 24 years. In this time the OPCW's reason to believe in the existence of undisclosed weapons has only grown––the most recent assessment saw "potentially undeclared full-scale development and production of chemical weapons at two declared chemical weapons-related facilities," said OPCW chief Fernando Arias in November. Extremist Acquisition of Weapons Prevented, Says Israel Israel has conducted airstrikes on suspected chemical weapons sites and long-range rocket facilities to prevent their acquisition by "extremists." "Since the initial hours after the announcement of the fall of the former regime, Israel began launching intensive air strikes, deliberately destroying weapons and ammunitions depots," UK-based monitoring group The Syrian Observatory for Human Rights (SOHR) said. Israel's foreign minister Gideon Saar on Monday said, "The only interest we have is the security of Israel and its citizens." "That's why we attacked strategic weapons systems, like, for example, remaining chemical weapons, or long-range missiles and rockets, in order that they will not fall in the hands of extremists." Russia Grants Assad Political Asylum Meanwhile, Assad has sought political asylum in Russia . Kremlin spokesperson Dmitry Peskov confirmed the arrangement but declined to comment on Assad's location or any planned meeting with Russian President Vladimir Putin . Assad's removal from power has created a political vacuum, with rebel leader Ahmad al-Sharaa—formerly known as Abu Mohammed al-Golani—emerging as a key figure. Assad has not made a public appearance since meeting with Iran's foreign minister in Damascus last week, where he pledged to "crush" the advancing rebels. Since then, forces led by former al-Qaeda commander Abu Mohammed al-Jawlani, now heading the militant group Hayat Tahrir al-Sham, have seized control of the capital and much of Assad's remaining territory. This article includes reporting from The Associated PressSnell, Dodgers agree to $182M, 5-year contractNone

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree” or "the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis [email protected] Consolidated Balance Sheets (in thousands, except share and per share data) Consolidated Statements of Operations (in thousands, except per share data)Techmediabreaks Quantum Computing Inc. (NASDAQ: QUBT) Announces Concurrent OfferingsDefensive back Genesis Smith to enter portal, upping Arizona’s transfer count to 30

Can We End Racism In Australia? Yes, According To The First-Ever National PlanFuture of Vertical Steam Sterilizers Market: Analysis and Leadership by Yamato Scientific, Matachana, Steelco, PRIMUS Sterilizer, Tuttnauer, Biobase, Steris, Shinva

FanDuel Promo Code: Steelers-Browns TNF $150 Bonus Offer

how to play super ace jili

jili super ace app download apk latest version

Related articles:
Latest News
Recommended Reading
Hot Recommendations
jollibee 6 pcs www jilibet.com

Copyright © 2015 jilibet slots All Rights Reserved.